Medication insights: teprotumumab-trbw (Tepezza) The U.S. Food and Drug Administration (FDA) first approved teprotumumab-trbw (Tepezza) in January 2020 for the treatment of thyroid eye disease...

Studies aim to highlight the impact of various healthcare strategies on patient outcomes and cost containment

Annual conference gathers 2,500+ managed care leaders to discuss complex health care issues.

Insights from Academy of Managed Care Pharmacy (AMCP) Nexus 2023

As assistant vice president of health outcomes, Gleason leads research into healthcare access, costs and outcomes, helping guide benefit strategies for payers and providers

Constant communication across the supply chain limits disruption when a drug is unavailable

Effective: January 2021 Terms of use IF YOU ARE EXPERIENCING A MEDICAL EMERGENCY, DIAL 911 AND/OR SEEK IMMEDIATE ATTENTION FROM A HEALTH CARE PROVIDER. THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE....

Zabrina Watkins Radical welcomeness “At Prime we’re committed to creating an open, inclusive culture that’s purpose-oriented and focused on providing meaningful work for our employees. To do this,...

A strategic deep dive into the latest trend report from Prime Therapeutics reveals how oncology spend is evolving across benefits and what it means for cancer care management

Sept. 27, 2024 - ustekinumab-aauz (Otulfi) Fresenius Kabi has received FDA approval for Otulfi as a biosimilar to ustekinumab (Stelara). This human interleukin (IL)-12 and IL-23 antagonist is...

Oncology Insights On May 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval to intravenous Imdelltra™ (tarlatamab) for the treatment of adults with relapsed/refractory...

Prime’s Special Investigations Unit is specially trained to protect patients and providers throughout the health care continuum

March 7, 2025 – rivaroxaban 2.5 mg tablet (Xarelto) Lupin launched a generic to Janssen’s Xarelto Factor Xa inhibitor indicated (1) to reduce the risk of major cardiovascular events in patients...

Tennessee In accordance with Texas Senate Bill 1236, Prime Therapeutics provides Texas-based pharmacies with secure online access to their pharmacy benefit network contracts that were executed on...

Heading Example Home Other Navigation Pharmacy + Providers Commercial Formularies Commercial formularies PrimeChoice Accord™ Formulary PrimeChoice Accord™ Formulary Updates NetResults™ A-Series...

Jessica Johnson, clinical consultant at Prime Therapeutics, shares some ways to avoid common fraud schemes

Cover image for FDA Decisions Expected_February 2025 Drug pipeline for February 2025 Prime Therapeutics /fda-decisions-expected-february-2025 About Prime Therapeutics Prime Therapeutics logo Prime...

Event features Pat Gleason, AVP, health outcomes at Prime Therapeutics

Cover image for FDA Decisions Expected: November 2024 Drug pipeline for November 2024 Prime Therapeutics /fda-decisions-expected-november-2024 Prime Therapeutics’ FDA Decisions Expected outlines...

New or expanded indications March 12, 2025 – fluocinolone acetonide intravitreal implant (Iluvien) Alimera; corticosteroid; supplemental NDA (sNDA) approved for consolidation of labeling of...